SG11201807537RA - Process for the preparation of an antibody-rifamycin conjugate - Google Patents

Process for the preparation of an antibody-rifamycin conjugate

Info

Publication number
SG11201807537RA
SG11201807537RA SG11201807537RA SG11201807537RA SG11201807537RA SG 11201807537R A SG11201807537R A SG 11201807537RA SG 11201807537R A SG11201807537R A SG 11201807537RA SG 11201807537R A SG11201807537R A SG 11201807537RA SG 11201807537R A SG11201807537R A SG 11201807537RA
Authority
SG
Singapore
Prior art keywords
hoffmann
basel
roche
international
dna
Prior art date
Application number
SG11201807537RA
Other languages
English (en)
Inventor
Stephan Bachmann
Serena Maria Fantasia
Michael Jansen
Stefan Koenig
Xin Linghu
Sebastian Rieth
Nathaniel L Segraves
Andreas Zogg
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201807537RA publication Critical patent/SG11201807537RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/78—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201807537RA 2016-03-04 2017-03-03 Process for the preparation of an antibody-rifamycin conjugate SG11201807537RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303556P 2016-03-04 2016-03-04
PCT/US2017/020711 WO2017152083A1 (fr) 2016-03-04 2017-03-03 Procédé de préparation d'un conjugué anticorps-rifamycine

Publications (1)

Publication Number Publication Date
SG11201807537RA true SG11201807537RA (en) 2018-09-27

Family

ID=58361102

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807537RA SG11201807537RA (en) 2016-03-04 2017-03-03 Process for the preparation of an antibody-rifamycin conjugate

Country Status (13)

Country Link
US (2) US10336683B2 (fr)
EP (1) EP3423457B1 (fr)
JP (2) JP6705904B2 (fr)
KR (1) KR102204805B1 (fr)
CN (1) CN108713020A (fr)
AR (1) AR107800A1 (fr)
AU (1) AU2017228468B2 (fr)
BR (1) BR112018014355A2 (fr)
CA (1) CA3012046C (fr)
IL (1) IL260465B (fr)
MX (1) MX2018010491A (fr)
SG (1) SG11201807537RA (fr)
WO (1) WO2017152083A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3012046C (fr) 2016-03-04 2020-11-10 Genentech, Inc. Procede de preparation d'un conjugue anticorps-rifamycine
CN108047250B (zh) * 2018-02-12 2020-08-14 丹诺医药(苏州）有限公司 一种利福霉素-硝基咪唑偶联分子的应用
CN110687217B (zh) * 2018-08-07 2021-04-23 中国科学院大连化学物理研究所 液相色谱测定利福霉素s的方法
CN110687218B (zh) * 2018-08-07 2021-04-23 中国科学院大连化学物理研究所 液相色谱测定苯并噁嗪利福霉素的方法
EP3897841A1 (fr) 2018-12-21 2021-10-27 Regeneron Pharmaceuticals, Inc. Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
WO2023023378A1 (fr) * 2021-08-20 2023-02-23 Rutgers, The State University Of New Jersey INHIBITEURS D'ARN POLYMÉRASE À DOUBLE CIBLE : CONJUGUÉS DE BENZOXAZINO- ET SPIRO-RIFAMYCINES AVEC Nα-AROYL- N-ARYL-PHÉNYLALANINAMIDES
CN114436864A (zh) * 2022-02-17 2022-05-06 浙江鼎龙科技股份有限公司 一种2-甲基-5氨基苯酚的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB877732A (en) 1958-08-12 1961-09-20 Lepetit Spa The antibiotic rifomycin, its components and methods of preparing same
US4690919A (en) 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS63183587A (ja) 1985-02-05 1988-07-28 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノリフアマイシン誘導体
CA1304363C (fr) 1988-11-01 1992-06-30 Takehiko Yamane Derive 3-hydroxybenzoxazinorifamycine, procede pour sa preparation et agent antibacterien en contenant
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
ES2556641T3 (es) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
CA2536378A1 (fr) 2003-08-22 2005-03-10 Activbiotics, Inc. Analogues de rifamycine et utilisations de ceux-ci
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005062882A2 (fr) 2003-12-23 2005-07-14 Activbiotics, Inc Analogues de rifamycine et leurs utilisations
US7265107B2 (en) 2004-03-10 2007-09-04 Cumbre Pharmaceuticals Inc. Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
MX2008007808A (es) 2005-12-14 2008-09-15 Activbiotics Pharma Llc Analogos de rifamicina y usos de ellos.
US7678791B2 (en) 2006-07-12 2010-03-16 Cumbre Ip Ventures, L.P. Nitroheteroaryl-containing rifamycin derivatives
PL2121920T3 (pl) 2007-03-01 2012-01-31 Symphogen As Sposób klonowania pokrewnych przeciwciał
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
ES2450755T3 (es) 2007-10-19 2014-03-25 Genentech, Inc. Anticuerpos anti-TENB2 modificados por ingeniería genética con cisteína, y conjugados de anticuerpo y fármaco
WO2009064792A1 (fr) 2007-11-16 2009-05-22 Cumbre Pharmaceuticals Inc. Dérivés de rifamycine substituée par l'acide quinolone-carboxylique
KR20100135711A (ko) * 2007-12-20 2010-12-27 엔비보 파마슈티칼즈, 인코퍼레이티드 사중치환된 벤젠
WO2010019511A2 (fr) 2008-08-13 2010-02-18 Targanta Therapeutics Corp. Rifamycines phosphonées et leurs utilisations pour la prévention et le traitement d'infections des os et des articulations
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
KR20150024315A (ko) 2012-05-07 2015-03-06 재단법인 목암생명공학연구소 포도상구균 감염 예방용 백신 조성물
JP6371758B2 (ja) 2013-03-12 2018-08-08 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
WO2014193722A1 (fr) 2013-05-31 2014-12-04 Genentech, Inc. Anticorps anti-acides téichoïques de paroi et leurs conjugués
SI3004162T1 (sl) * 2013-05-31 2020-07-31 Genentech, Inc. Protitelesa in konjugati, ki so usmerjeni proti celični steni bakterij, v kateri je teihoična kislina
TWI632157B (zh) * 2013-05-31 2018-08-11 建南德克公司 抗壁磷壁酸抗體（ａｎｔｉ－ｗａｌｌ ｔｅｉｃｈｏｉｃ ａｃｉｄ ａｎｔｉｂｏｄｉｅｓ）及結合物
RU2731055C2 (ru) * 2014-12-03 2020-08-28 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
RU2017118792A (ru) * 2014-12-03 2019-01-09 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
CA3012046C (fr) 2016-03-04 2020-11-10 Genentech, Inc. Procede de preparation d'un conjugue anticorps-rifamycine

Also Published As

Publication number Publication date
CA3012046C (fr) 2020-11-10
EP3423457B1 (fr) 2021-02-17
IL260465B (en) 2020-11-30
WO2017152083A1 (fr) 2017-09-08
JP6705904B2 (ja) 2020-06-03
US20170252457A1 (en) 2017-09-07
KR20180118173A (ko) 2018-10-30
CA3012046A1 (fr) 2017-09-08
US10689325B2 (en) 2020-06-23
AU2017228468A1 (en) 2018-07-26
MX2018010491A (es) 2018-11-09
KR102204805B1 (ko) 2021-01-20
AR107800A1 (es) 2018-06-06
BR112018014355A2 (pt) 2018-12-18
AU2017228468B2 (en) 2019-12-05
EP3423457A1 (fr) 2019-01-09
JP2020090506A (ja) 2020-06-11
JP2019510740A (ja) 2019-04-18
US20190270695A1 (en) 2019-09-05
US10336683B2 (en) 2019-07-02
CN108713020A (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
SG11201807537RA (en) Process for the preparation of an antibody-rifamycin conjugate
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811432WA (en) Rna for cancer therapy
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201807187XA (en) Binding members to pd-l1
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201901531TA (en) Regulation of gene expression using engineered nucleases
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201909011PA (en) Niraparib compositions
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists